Skip to main content
Top
Published in: Rheumatology International 12/2010

01-11-2010 | Original Article

Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus

Authors: Fumio Sekiya, Ken Yamaji, Kwangseok Yang, Hiroshi Tsuda, Yoshinari Takasaki

Published in: Rheumatology International | Issue 12/2010

Login to get access

Abstract

Osteonecrosis (ON) of the femoral head is known to occur commonly in cases with systemic lupus erythematosus (SLE) that received corticosteroid (CS) treatment. However, there have been no detailed reports about the onset of ON in cases with recurrence of SLE. Using MRI, we followed up 17 patients who experienced recurrence of SLE for at least 1 year at our hospital and in whom the CS dose was increased from a maintenance dose to middle to high dose to see if ON would occur. We then compared the group that developed ON and the group that did not with respect to patient characteristics, blood test results, changes in serum lipid levels, and CS dose. ON occurred in five subjects (29.4%), revealing that osteonecrosis occurs not only when CS are first administered but also in cases which the CS dose is increased for recurrence of SLE. Especially, serum cholesterol levels and its rate of increase soared rapidly soon after increasing the CS dose in the ON group as compared with the non-ON group (P < 0.05). This suggests that increased serum lipid levels might be a contributing factor to onset of ON. Moreover, SLE disease activity index 2000 (SLEDAI-2K) scores when the CS dose was increased were significantly (P < 0.05) higher in the ON group, suggesting that SLE disease activity itself is a risk factor for onset of ON.
Literature
1.
go back to reference Moskal JT, Topping RE, Franklin LL (1997) Hypercholesterolemia: an association with osteonecrosis of the femoral head. Am J Orthop 26:609–612PubMed Moskal JT, Topping RE, Franklin LL (1997) Hypercholesterolemia: an association with osteonecrosis of the femoral head. Am J Orthop 26:609–612PubMed
2.
go back to reference Oinuma K, Harada Y, Nawata Y et al (2000) Sustained hemostatic abnormality in patients with steroid-induced osteonecrosis in the early period after high-dose corticosteroid therapy. J Orthop Sci 5:374–379CrossRefPubMed Oinuma K, Harada Y, Nawata Y et al (2000) Sustained hemostatic abnormality in patients with steroid-induced osteonecrosis in the early period after high-dose corticosteroid therapy. J Orthop Sci 5:374–379CrossRefPubMed
3.
go back to reference Iuchi T, Akaike M, Mitsui T et al (2003) Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 92:81–87CrossRefPubMed Iuchi T, Akaike M, Mitsui T et al (2003) Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 92:81–87CrossRefPubMed
4.
go back to reference Klippel JH, Gerber LH, Pollak L, Decker JL (1979) Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses. Am J Med 67:83–87CrossRefPubMed Klippel JH, Gerber LH, Pollak L, Decker JL (1979) Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses. Am J Med 67:83–87CrossRefPubMed
5.
go back to reference Ono K, Tohjima T, Komazawa T (1992) Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop Relat Res 277:89–97PubMed Ono K, Tohjima T, Komazawa T (1992) Risk factors of avascular necrosis of the femoral head in patients with systemic lupus erythematosus under high-dose corticosteroid therapy. Clin Orthop Relat Res 277:89–97PubMed
6.
go back to reference Migliaresi S, Picillo U, Ambrosone L et al (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3:37–41CrossRefPubMed Migliaresi S, Picillo U, Ambrosone L et al (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3:37–41CrossRefPubMed
7.
go back to reference Mont MA, Glueck CJ, Pacheco IH et al (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24:654–662PubMed Mont MA, Glueck CJ, Pacheco IH et al (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24:654–662PubMed
8.
go back to reference Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37:895–900CrossRefPubMed Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37:895–900CrossRefPubMed
9.
go back to reference Sakamoto M, Shimizu K, Iida S et al (1997) Osteonecrosis of the femoral head: a prospective study with MRI. J Bone Joint Surg Br 79:213–219CrossRefPubMed Sakamoto M, Shimizu K, Iida S et al (1997) Osteonecrosis of the femoral head: a prospective study with MRI. J Bone Joint Surg Br 79:213–219CrossRefPubMed
10.
go back to reference Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725CrossRefPubMed
11.
go back to reference Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed
12.
go back to reference Fukushima W et al (2007) In: Kubo T (ed) The general study aimed for standardization of the prevention and the treatment of the idiopathic osteonecrosis of the femoral head. Research Group of the idiopathic osteonecrosis of the femoral head, Ministry of Health, Labor, and Welfare of Japan. pp 7–11 (in Japanese) Fukushima W et al (2007) In: Kubo T (ed) The general study aimed for standardization of the prevention and the treatment of the idiopathic osteonecrosis of the femoral head. Research Group of the idiopathic osteonecrosis of the femoral head, Ministry of Health, Labor, and Welfare of Japan. pp 7–11 (in Japanese)
13.
go back to reference Hirota Y, Hirohata T, Fukuda K et al (1993) Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head. Am J Epidemiol 137:530–538PubMed Hirota Y, Hirohata T, Fukuda K et al (1993) Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head. Am J Epidemiol 137:530–538PubMed
14.
go back to reference Matsuo K, Hirohata T, Sugioka Y et al (1988) Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 234:115–123PubMed Matsuo K, Hirohata T, Sugioka Y et al (1988) Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 234:115–123PubMed
15.
go back to reference Mont MA, Jones LC, Hungerford DS (2006) Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88:1117–1132 ReviewCrossRefPubMed Mont MA, Jones LC, Hungerford DS (2006) Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88:1117–1132 ReviewCrossRefPubMed
16.
go back to reference Agarwala S, Jain D, Joshi VR et al (2005) Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44:352–359CrossRef Agarwala S, Jain D, Joshi VR et al (2005) Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44:352–359CrossRef
17.
go back to reference Lai KA, Shen WJ, Yang CY et al (2005) The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87:2155–2159CrossRefPubMed Lai KA, Shen WJ, Yang CY et al (2005) The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 87:2155–2159CrossRefPubMed
18.
go back to reference Nishii T, Sugano N, Miki H et al (2006) Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 443:273–279CrossRefPubMed Nishii T, Sugano N, Miki H et al (2006) Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res 443:273–279CrossRefPubMed
19.
go back to reference Cui Q, Wang GJ, Su CC et al (1997) Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Relat Res 344:8–19CrossRefPubMed Cui Q, Wang GJ, Su CC et al (1997) Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Relat Res 344:8–19CrossRefPubMed
20.
go back to reference Pritchett JW (2001) Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res 386:173–178CrossRefPubMed Pritchett JW (2001) Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res 386:173–178CrossRefPubMed
21.
go back to reference Nagasawa K, Tada Y, Koarada S et al (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14:385–390CrossRefPubMed Nagasawa K, Tada Y, Koarada S et al (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14:385–390CrossRefPubMed
22.
go back to reference Miyanishi K, Yamamoto T, Irisa T et al (2001) A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits. Rheumatology (Oxford) 40:196–201CrossRef Miyanishi K, Yamamoto T, Irisa T et al (2001) A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits. Rheumatology (Oxford) 40:196–201CrossRef
23.
go back to reference Lafforgue P (2006) Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 73:500–507 ReviewCrossRefPubMed Lafforgue P (2006) Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine 73:500–507 ReviewCrossRefPubMed
24.
go back to reference Massardo L, Jacobeli S, Leissner M et al (1992) High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1:401–405CrossRefPubMed Massardo L, Jacobeli S, Leissner M et al (1992) High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus 1:401–405CrossRefPubMed
25.
go back to reference Asano T, Takahashi KA, Fujioka M et al (2003) ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13:675–682CrossRefPubMed Asano T, Takahashi KA, Fujioka M et al (2003) ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13:675–682CrossRefPubMed
26.
go back to reference Hirata T, Fujioka M, Takahashi KA et al (2007) ApoB C7623T polymorphism predicts risk for steroid-induced osteonecrosis of the femoral head after renal transplantation. J Orthop Sci 12:199–206CrossRefPubMed Hirata T, Fujioka M, Takahashi KA et al (2007) ApoB C7623T polymorphism predicts risk for steroid-induced osteonecrosis of the femoral head after renal transplantation. J Orthop Sci 12:199–206CrossRefPubMed
27.
go back to reference Fialho SC, Bonfá E, Vitule LF et al (2007) Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16:239–244CrossRefPubMed Fialho SC, Bonfá E, Vitule LF et al (2007) Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16:239–244CrossRefPubMed
Metadata
Title
Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus
Authors
Fumio Sekiya
Ken Yamaji
Kwangseok Yang
Hiroshi Tsuda
Yoshinari Takasaki
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1194-y

Other articles of this Issue 12/2010

Rheumatology International 12/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine